SCHEMBL5635147

SCHEMBL5635147

CCc1nccnc1C(=O)c1cnc(Nc2cccc(S(N)(=O)=O)c2)s1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 3/20 0.46
CDK2 P24941 3/20 0.46
CCNT1 O60563 2/20 0.44
CDK1 P06493 2/20 0.44
CCNB1 P14635 2/20 0.44
CDK7 P50613 2/20 0.44
CDK9 P50750 2/20 0.44
CCNH P51946 2/20 0.44
CCNA1 P78396 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPK13 O15264 5/20 0.43
MAPK12 P53778 5/20 0.43
MAPK11 Q15759 5/20 0.43
MAPK14 Q16539 5/20 0.43
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5634191 0.84 CDK2 (0.49) CCNA2CDK2CCNT1CDK1CCNB1
SCHEMBL5634568 0.82 MAPK13 (0.54) CCNA2CDK2CCNT1CDK1CCNB1
SCHEMBL5636032 0.82 NPC1 (0.45) NPC1RAB9ASMN1; SMN2MAPK13MAPK12
SCHEMBL5634234 0.79 MAPK13 (0.69) CCNA2CDK2NPC1RAB9ASMN1; SMN2
SCHEMBL5633608 0.78 MAPK13 (0.56) CCNA2CDK2NPC1RAB9ASMN1; SMN2
SCHEMBL5635589 0.78 CDK2 (0.51) CCNA2CDK2CCNT1CDK1CCNB1
SCHEMBL5634314 0.77 NPC1 (0.48) CCNA2CDK2CCNT1CDK1CCNB1
SCHEMBL5634268 0.76 MAPK13 (0.74) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5634686 0.76 MAPK13 (0.55) CCNA2CDK2NPC1RAB9ASMN1; SMN2
SCHEMBL5634101 0.76 MAPK13 (0.56) NPC1RAB9AMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100381429-C Thiazole derivatives HOFFMANN LA ROCHE (CH) 2008-04-16 CN disclosed
US-7253197-B2 Aminothiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
CN-1675188-A Thiazole derivatives HOFFMANN LA ROCHE (CH) 2005-09-28 CN disclosed
EP-1539722-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-15 EP disclosed
US-20040038990-A1 Aminothiazole derivatives HOFFMANN-LA ROCHE INC. 2004-02-26 US disclosed
WO-2004014884-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038990-A1 Aminothiazole derivatives FABP4, GPR119, ABAT CCNA2 4025/4885CDK2 2572/4885CCNT1 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.